Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
0.2736
+0.0036 (1.33%)
At close: Apr 1, 2025, 4:00 PM
0.2856
+0.0120 (4.39%)
After-hours: Apr 1, 2025, 4:34 PM EDT
Relmada Therapeutics Employees
Relmada Therapeutics had 20 employees as of December 31, 2023. The number of employees increased by 6 or 42.86% compared to the previous year.
Employees
20
Change (1Y)
6
Growth (1Y)
42.86%
Revenue / Employee
n/a
Profits / Employee
-$3,998,968
Market Cap
8.26M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RLMD News
- 4 days ago - Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - GlobeNewsWire
- 6 days ago - Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 - GlobeNewsWire
- 7 days ago - Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. - GlobeNewsWire
- 7 weeks ago - Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB - GlobeNewsWire
- 4 months ago - Relmada discontinues late-stage trials for depression drug, explores sale - Reuters
- 4 months ago - Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017 - GlobeNewsWire
- 4 months ago - Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why - Benzinga